These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 4834709)

  • 41. [Treatment of outpatients with high doses of haloperidol].
    Shopsin B; Kline N
    Acta Psiquiatr Psicol Am Lat; 1981 Jul; 27(3):236-42. PubMed ID: 7348083
    [No Abstract]   [Full Text] [Related]  

  • 42. Withdrawal syndromes associated with antipsychotic drugs.
    Gardos G; Cole JO; Tarsy D
    Am J Psychiatry; 1978 Nov; 135(11):1321-4. PubMed ID: 30287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention and management of tardive dyskinesia.
    Crane GE
    Am J Psychiatry; 1972 Oct; 129(4):466-7. PubMed ID: 5071149
    [No Abstract]   [Full Text] [Related]  

  • 44. Haloperidol in psychiatry.
    Med Lett Drugs Ther; 1975 Jan; 17(3):11-2. PubMed ID: 1092991
    [No Abstract]   [Full Text] [Related]  

  • 45. Withdrawal akathisia: case reports and a proposed classification of chronic akathisia.
    Lang AE
    Mov Disord; 1994 Mar; 9(2):188-92. PubMed ID: 8196681
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroleptic discontinuation and tardive dyskinesia risk.
    Sherr JD; Medoff D; Thaker G
    Am J Psychiatry; 1999 Jul; 156(7):1125-6. PubMed ID: 10401483
    [No Abstract]   [Full Text] [Related]  

  • 47. Dexetimide (R 16470) in the control of neuroleptic-induced extrapyramidal side-effects. Its prophylactic value and duration of action.
    Huygens H; Vereecken JL; Tanghe A
    Psychiatr Neurol Neurochir; 1973; 76(4):251-9. PubMed ID: 4581374
    [No Abstract]   [Full Text] [Related]  

  • 48. Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.
    Sramek JJ; Simpson GM; Morrison RL; Heiser JF
    J Clin Psychiatry; 1986 Jun; 47(6):305-9. PubMed ID: 2872206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [On the problem of the therapeutical axis symptom of neuroleptic medicaments].
    Glatzel J
    Psychiatr Neurol Med Psychol (Leipz); 1968 Aug; 20(8):286-95. PubMed ID: 5731884
    [No Abstract]   [Full Text] [Related]  

  • 50. Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics?
    Henkel V; Mergl R; Schäfer M; Rujescu D; Möller HJ; Hegerl U
    Pharmacopsychiatry; 2004 May; 37(3):110-8. PubMed ID: 15138894
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Haloperidol-induced tardive dyskinesia in a 10-year-old girl.
    Petty LK; Spar CJ
    Am J Psychiatry; 1980 Jun; 137(6):745-6. PubMed ID: 7377407
    [No Abstract]   [Full Text] [Related]  

  • 52. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
    Bransgrove LL; Kelly MW
    Am J Hosp Pharm; 1994 Apr; 51(7):895-9. PubMed ID: 7912473
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuation.
    Mendhekar DN; Jiloha RC
    Aust N Z J Psychiatry; 2005 Oct; 39(10):947-8. PubMed ID: 16168023
    [No Abstract]   [Full Text] [Related]  

  • 54. Phobic behavior after haloperidol withdrawal.
    Mizes JS
    Am J Psychiatry; 1984 Apr; 141(4):612. PubMed ID: 6703151
    [No Abstract]   [Full Text] [Related]  

  • 55. [Antagonism between anti-Parkinson drugs and neuroleptics. Apropos of various withdrawal experiences, a personal one among them (2nd part)].
    Bourgeois M; Bouey P
    Ann Med Psychol (Paris); 1976 Nov; 2(4):669-708. PubMed ID: 1020864
    [No Abstract]   [Full Text] [Related]  

  • 56. Drug induced extrapyramidal effects--a review.
    Coleman JH; Hayes PE
    Dis Nerv Syst; 1975 Oct; 36(10):591-3. PubMed ID: 1100334
    [No Abstract]   [Full Text] [Related]  

  • 57. Haloperidol dosing strategies.
    Schooler NR
    Am J Psychiatry; 1996 Aug; 153(8):1108; author reply 1109. PubMed ID: 8678185
    [No Abstract]   [Full Text] [Related]  

  • 58. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tardive dyskinesia and the rabbit syndrome during wakefulness and sleep.
    Jus K; Villeneuve A; Jus A
    Am J Psychiatry; 1972 Dec; 129(6):765. PubMed ID: 4638729
    [No Abstract]   [Full Text] [Related]  

  • 60. Long-term effects of haloperidol.
    Man PL
    Dis Nerv Syst; 1973 Feb; 34(2):113-8. PubMed ID: 4267586
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.